Vitamin B1/Thiamine / AGEs Cancer Research Results

VitB1/Thiamine, Vitamin B1/Thiamine: Click to Expand ⟱
Features:
VitB1/Thiamine
Vitamin B1 (thiamine) is an essential water-soluble vitamin required for carbohydrate metabolism and mitochondrial energy production. Its active form, thiamine pyrophosphate (TPP), is a cofactor for key enzymes including pyruvate dehydrogenase (PDH), α-ketoglutarate dehydrogenase (α-KGDH), and transketolase. In Alzheimer’s disease (AD), thiamine deficiency and reduced activity of thiamine-dependent enzymes have been repeatedly observed in brain tissue. Impaired glucose metabolism is a hallmark of AD (“type 3 diabetes” hypothesis), and thiamine-dependent enzyme dysfunction contributes to mitochondrial impairment, oxidative stress, and neuronal vulnerability. Experimental studies suggest thiamine and lipophilic derivatives (e.g., benfotiamine) may improve glucose metabolism, reduce advanced glycation end products (AGEs), attenuate oxidative stress, and modulate neuroinflammation. Clinical data are mixed but suggest possible benefit in selected populations or with higher-bioavailability derivatives.
Benfotiamine is a fat-soluble derivative of vitamin B1 (thiamine) that’s used to support nerve health, glucose metabolism, and potentially brain function, including in conditions like Alzheimer’s disease (AD) and diabetic neuropathy.
-fat-soluble form, so may absorb better when taken with a meal containing fat.
Condition / Purpose	       Typical Dose Range	Notes
Alzheimer’s Disease (AD)	300–600 mg/day	        Used in clinical trials (e.g., 300 mg twice daily)
Diabetic Neuropathy	        300–600 mg/day	        Most common clinical application
General Cognitive Support	150–300 mg/day	        Lower end for maintenance
High-dose experimental use	900–1,200 mg/day	Occasionally used under supervision in research

Alzheimer’s Disease Table: Vitamin B1 (Thiamine)

Rank Pathway / Axis AD / Neurodegeneration Context Normal Brain Context TSF Primary Effect Notes / Interpretation
1 Pyruvate dehydrogenase (PDH) activity PDH activity ↓ in AD; thiamine restores PDH flux Glucose oxidation support R, G Mitochondrial energy restoration PDH links glycolysis to TCA cycle; impairment contributes to cerebral hypometabolism in AD.
2 α-Ketoglutarate dehydrogenase (α-KGDH) α-KGDH ↓ in AD brain tissue TCA cycle support R, G Mitochondrial stabilization Enzyme reduction correlates with oxidative stress and neuronal vulnerability.
3 Transketolase / Pentose Phosphate Pathway (PPP) NADPH production ↑; oxidative stress ↓ Redox buffering R, G Antioxidant support Transketolase requires thiamine; PPP supports glutathione regeneration.
4 Mitochondrial bioenergetics ATP production ↑; mitochondrial efficiency ↑ Energy metabolism normalization R Bioenergetic restoration Addresses cerebral glucose hypometabolism seen in AD imaging studies.
5 Oxidative stress reduction ROS ↓; lipid peroxidation ↓ (reported) Redox balance support R, G Antioxidant effect (indirect) Improved mitochondrial function reduces ROS generation.
6 Advanced glycation end products (AGEs) AGE formation ↓ (reported with benfotiamine) Glycation moderation G Metabolic toxicity reduction Benfotiamine may reduce glycation-linked neuronal damage.
7 Neuroinflammation Inflammatory markers ↓ (model-dependent) Inflammation moderation R, G Secondary anti-inflammatory effect Likely indirect via improved metabolic and redox function.
8 Amyloid / tau pathology Indirect modulation reported in models ↔ G Disease-modifying potential (uncertain) No strong direct anti-amyloid mechanism; effects appear metabolic.
9 Clinical cognition outcomes Mixed results; some benefit with benfotiamine Safe at standard doses G Adjunctive support High-dose or derivative forms may show more promise than standard thiamine.
10 Bioavailability / derivative consideration Benfotiamine & lipid-soluble forms ↑ CNS penetration Well tolerated — Translation constraint Standard thiamine has limited brain penetration; benfotiamine shows improved pharmacokinetics.

TSF: P = minimal immediate effect; R = metabolic enzyme activation; G = long-term neuroprotective adaptation.



Thiamine vs Benfotiamine Comparison Table

Feature Thiamine (Vitamin B1) Benfotiamine
Chemical form Water-soluble vitamin (thiamine hydrochloride or mononitrate) Lipid-soluble S-acyl thiamine derivative
Absorption mechanism Active transport (THTR-1/2) in small intestine Passive diffusion (lipophilic); higher bioavailability
Plasma thiamine levels Moderate increase with supplementation Significantly higher plasma thiamine after oral dosing
Brain penetration Limited; regulated transport Indirectly increases brain thiamine via systemic elevation; better tissue distribution
Activation Converted to thiamine pyrophosphate (TPP) intracellularly Converted to thiamine → TPP intracellularly
PDH / α-KGDH support Restores enzyme activity in deficiency Stronger elevation of transketolase & TPP-dependent activity (reported)
Pentose phosphate pathway (PPP) Supports transketolase → NADPH production More pronounced activation of transketolase reported
AGE reduction Limited direct evidence Strong evidence for reducing advanced glycation end products (AGEs)
Oxidative stress impact Indirect ROS reduction via improved metabolism Stronger reduction of glycation-related oxidative stress
AD clinical evidence Mixed, limited benefit in trials Small trials suggest potential cognitive stabilization
Dose ranges studied (AD/metabolic) 100–300 mg/day (varies) 150–600 mg/day commonly studied
Safety profile Very safe; excess excreted in urine Generally safe; mild GI symptoms possible
Primary AD positioning Correct deficiency; metabolic support Enhanced metabolic + anti-glycation support
Best-fit scenario Thiamine deficiency; mild metabolic impairment Glucose dysregulation; high AGE burden; metabolic AD phenotype


AGEs, Advanced Glycation End Products: Click to Expand ⟱
Source:
Type:
Advanced Glycation End Products (AGEs) are highly reactive compounds formed when proteins or lipids become non-enzymatically glycated after exposure to sugars. AGEs accumulate with age and are implicated in various chronic diseases—including Alzheimer’s disease (AD).
-AGEs bind to Aβ peptides, increasing aggregation and plaque stability.
-AGEs activate kinases like GSK-3β and p38 MAPK, promoting tau phosphorylation.
-Human brains with AD show increased AGE-modified proteins and elevated RAGE expression.
-Blocking RAGE or reducing AGEs slows cognitive decline and pathology in mice.

Strategies to Reduce AGE Burden
-Low-AGE cooking (steaming, boiling), Mediterranean diet
- reduce processed meats, sugary baked goods, and fried foods.
Scientific Papers found: Click to Expand⟱
4311- VitB1/Thiamine,    Benfotiamine treatment activates the Nrf2/ARE pathway and is neuroprotective in a transgenic mouse model of tauopathy
- in-vivo, AD, NA
*Aβ↓, *p‑tau↓, *ROS↓, *cognitive↑, *OS↑, *Mood↑, *neuroP↑, *Inflam↓, *NRF2↑, *PGC-1α↑, *AGEs↓, *4-HNE↓, *NQO1↑, *COX2↓, *TNF-α↓, *IL1β↓, *NF-kB↓, *GSK‐3β↓,
4312- VitB1/Thiamine,    Pharmacological thiamine levels as a therapeutic approach in Alzheimer's disease
- Review, AD, NA
*eff↑, *cognitive↑, *memory↑, *GlucoseCon↑, *Aβ↓, *Inflam↓, *antiOx↑, *p‑tau↓, *AGEs↓, *Dose↝,

Showing Research Papers: 1 to 2 of 2

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 2

Pathway results for Effect on Cancer / Diseased Cells:


Total Targets: 0

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress ⓘ

4-HNE↓, 1,   antiOx↑, 1,   NQO1↑, 1,   NRF2↑, 1,   ROS↓, 1,  

Mitochondria & Bioenergetics ⓘ

PGC-1α↑, 1,  

Core Metabolism/Glycolysis ⓘ

GlucoseCon↑, 1,  

Proliferation, Differentiation & Cell State ⓘ

GSK‐3β↓, 1,  

Immune & Inflammatory Signaling ⓘ

COX2↓, 1,   IL1β↓, 1,   Inflam↓, 2,   NF-kB↓, 1,   TNF-α↓, 1,  

Synaptic & Neurotransmission ⓘ

p‑tau↓, 2,  

Protein Aggregation ⓘ

AGEs↓, 2,   Aβ↓, 2,  

Drug Metabolism & Resistance ⓘ

Dose↝, 1,   eff↑, 1,  

Functional Outcomes ⓘ

cognitive↑, 2,   memory↑, 1,   Mood↑, 1,   neuroP↑, 1,   OS↑, 1,  
Total Targets: 23

Scientific Paper Hit Count for: AGEs, Advanced Glycation End Products
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:264  Target#:1375  State#:%  Dir#:1
  wNotes=0  sortOrder:rid,rpid

 

Home Page